Company / Gross Margin
Lineage Cell Therapeutics, Inc. Gross Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
92.5%
FY2023
5-year range
67.2% / 92.5%
FY2019-FY2023
Trend
+37.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Margin returned to growth in FY2023 after 4 years of decline, reaching 92.5%.
Based on SEC 10-K filings.
92.5% in FY2023 with a 5-year CAGR of -2.6%.
Improved from 78.9% to 92.5% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +4.2pp
- 5-Year Change
- -2.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, gross margin increased 37.8% year-over-year.
- Peak gross margin was recorded in FY2018.
- Lowest gross margin in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | 92.5% | +37.8% |
| FY2022 | 67.2% | -14.9% |
| FY2021 | 78.9% | -10.6% |
| FY2020 | 88.3% | -6.0% |
| FY2019 | 94.0% | -1.3% |
| FY2018 | 95.1% | +12.9% |
| FY2017 | 84.3% | +0.3% |
| FY2016 | 84.0% | +2.3% |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026